PIPELINE

DRUG CANDIDATE

TARGET

INDICATION

PLATFORM

DISCOVERY

PRECLINICAL

PhI Dose Escalation

PhI Proof Of Concept

PhII Pivotal Study

RS-0139	Integrin	NSCL CA	SagittaTM Bir	ClinicalTrials.gov Identifier: NCT04261413
	Integrin	Breast CA	SagittaTM Bir
	Integrin	Prostate CA	SagittaTM Bir
	Integrin	Ovarian CA	SagittaTM Bir
	Integrin	Head & Neck CA	SagittaTM Bir
RS-0337	HER2	Breast CA	SagittaTM Dui
	HER2	Stomach CA	SagittaTM Dui
RS-0461	Integrin	Ovarian CA	SagittaTM Dui
RS-0625	Integrin	Ovarian CA	SagittaTM Bir
RS-0735	Undisclosed	Pancreas CA	SagittaTM Bir

DRUG	TARGET	INDICATION	PLATFORM	PHASE

RS-0139	Integrin	NSCL CA	SagittaTM Bir	PhI Dose Escalation
RS-0139	Integrin	Breast CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Prostate CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Ovarian CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Head&Neck CA	SagittaTM Bir	Preclinical
RS-0337	HER2	Breast CA	SagittaTM Dui	Preclinical
RS-0337	HER2	Stomach CA	SagittaTM Dui	Preclinical
RS-0461	Integrin	Ovarian CA	SagittaTM Dui	Preclinical
RS-0625	Integrin	Ovarian CA	SagittaTM Bir	Preclinical
RS-0735	Undisclosed	Pancreas CA	SagittaTM Bir	Preclinical

DRUG	TARGET	INDICATION	PLATFORM	PHASE

RS-0139	Integrin	NSCL CA	SagittaTM Bir	PhI Dose Escalation
RS-0139	Integrin	Breast CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Prostate CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Ovarian CA	SagittaTM Bir	Preclinical
RS-0139	Integrin	Head&Neck CA	SagittaTM Bir	Preclinical
RS-0337	HER2	Breast CA	SagittaTM Dui	Preclinical
RS-0337	HER2	Stomach CA	SagittaTM Dui	Preclinical
RS-0461	Integrin	Ovarian CA	SagittaTM Dui	Preclinical
RS-0625	Integrin	Ovarian CA	SagittaTM Bir	Preclinical
RS-0735	Undisclosed	Pancreas CA	SagittaTM Bir	Preclinical